Literature DB >> 1971427

Improvement of the oral bioavailability of the selective dopamine agonist N-0437 in rats: the in vitro and in vivo activity of eight ester prodrugs.

I den Daas1, P G Tepper, A S Horn.   

Abstract

The potent and selective D2-agonist N-0437 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin undergoes considerable first-pass metabolism due to glucuronidation of the phenolic group after oral administration. In an attempt to improve the bioavailability, eight ester prodrugs of N-0437 were synthesized, i.e. the acetyl, isobutyryl, pivaloyl, benzoyl, 2-methylbenzoyl, 2-methoxybenzoyl, 2,4-dimethylbenzoyl and 2-aminobenzoyl analogues. To examine the hydrolysis rates of these compounds in vitro studies were performed in rat serum. The prodrugs showed a very diverse pattern of hydrolysis rates. The in vivo activities were determined by testing the prodrugs in rats with unilateral 6-OHDA lesions of the striatum. The resulting contralateral turning was used to measure the activity of the compounds. By calculating the area under the curve (AUC), of the time-effect curves of the prodrugs, a significantly improved duration of action was found for those prodrugs which have a slow in vitro hydrolysis rate. However no significant differences in total activity of these slowly hydrolysing prodrugs compared with N-0437 could be demonstrated, although the 2-aminobenzoyl and the 2,4-dimethylbenzoyl derivatives show interesting behavioural profiles. In contrast the isobutyryl ester, a prodrug with a relatively rapid hydrolysis rate, gave an improvement of turning behaviour over the whole time course in comparison with N-0437.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971427     DOI: 10.1007/bf00169729

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Rationale for design of biologically reversible drug derivatives: prodrugs.

Authors:  A A Sinkula; S H Yalkowsky
Journal:  J Pharm Sci       Date:  1975-02       Impact factor: 3.534

2.  Prodrug behaviour of nicotinoylmorphine esters.

Authors:  C L Broekkamp; S K Oosterloo; H W Rijk
Journal:  J Pharm Pharmacol       Date:  1988-06       Impact factor: 3.765

3.  Hydrolysis of diester prodrugs of apomorphine.

Authors:  R J Baldessarini; N S Kula; K G Walton; R J Borgman
Journal:  Biochem Pharmacol       Date:  1977-10-01       Impact factor: 5.858

4.  Analysis of the dopamine agonist N-0437 in rat serum using reversed-phase high-performance liquid chromatography with electrochemical detection.

Authors:  I den Daas; H Rollema; J B de Vries; P G Tepper; A S Horn
Journal:  J Chromatogr       Date:  1989-01-27

5.  Buccal and oral bioavailability of nalbuphine in rats.

Authors:  M A Hussain; B J Aungst; E Shefter
Journal:  J Pharm Sci       Date:  1986-02       Impact factor: 3.534

6.  Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach.

Authors:  M A Hussain; C A Koval; M J Myers; E G Shami; E Shefter
Journal:  J Pharm Sci       Date:  1987-05       Impact factor: 3.534

7.  In vitro binding of the very potent and selective D-2 dopamine agonist, [3H]N-0437 to calf caudate membranes.

Authors:  J Van der Weide; J B De Vries; P G Tepper; A S Horn
Journal:  Eur J Pharmacol       Date:  1987-02-10       Impact factor: 4.432

8.  Carbamate ester derivatives as potential prodrugs of the presynaptic dopamine autoreceptor agonist (-)-3-(3-hydroxyphenyl)-N-propylpiperidine.

Authors:  S O Thorberg; S Berg; J Lundström; B Pettersson; A Wijkström; D Sanchez; P Lindberg; J L Nilsson
Journal:  J Med Chem       Date:  1987-11       Impact factor: 7.446

9.  The metabolic fate of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration. II. Isolation and identification of metabolites.

Authors:  T K Gerding; B F Drenth; R A de Zeeuw; P G Tepper; A S Horn
Journal:  Xenobiotica       Date:  1990-05       Impact factor: 1.908

10.  Brain levels and metabolism of the dopaminergic agonist 2-amino-6,7-dihydroxytetrahydronaphthalene after administration of various prodrugs.

Authors:  A S Horn; H Griever-Kazemier; D Dijkstra
Journal:  J Med Chem       Date:  1982-08       Impact factor: 7.446

View more
  4 in total

1.  Proceedings of the British Pharmacological Society Meeting. Sheffield, 18-20th April 1990.

Authors: 
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

2.  Pharmacological profile of non-hydroxylated and ether derivatives of the potent D2-selective agonist N-0437.

Authors:  J M Jansen; I den Daas; H Rollema; P J Swart; P G Tepper; J B de Vries; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

3.  Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model.

Authors:  I den Daas; P G Tepper; H Rollema; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

Review 4.  Antiparkinson prodrugs.

Authors:  Antonio Di Stefano; Piera Sozio; Laura Serafina Cerasa
Journal:  Molecules       Date:  2008-01-16       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.